Why the study?
Little was known regarding the rate of anthracycline-related acute and chronic cardiotoxicity and adherence to cardiac monitoring recommendations among cancer patients.
What is the incidence of cardiotoxicity and adherence to cardiac monitoring guidelines among cancer patients treated with anthracyclines?
What is the incidence of cardiotoxicity and adherence to cardiac monitoring guidelines among cancer patients treated with anthracyclines?
There is a high incidence of anthracycline-induced cardiotoxicity and poor adherence to ASCO cardiac monitoring guidelines in cancer patients.
No takes yet. Share an insight, caveat, or question.
High cardiotoxicity incidence with low monitoring adherence signals need for better surveillance; leaves open optimal real-world strategies.
Alkofide et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: